Fudan University affiliated Huashan Hospital
Welcome,         Profile    Billing    Logout  
 44 Trials 
53 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide(TMF), HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated
2/3
381
RoW
JT001, VV116, Placebo
Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH
Mild to Moderate COVID-19
03/23
03/23
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting
2/3
1188
RoW
FB2001, DC402234, FB2001 placebo
Frontier Biotechnologies Inc.
COVID-19
11/23
12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
07/27
07/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
Zhang, Jing
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed
3
458
RoW
608 Q2W, 608 Q4W, Placebo, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
10/23
06/24
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting
3
360
Europe, US, RoW
Elamipretide, Elamipretide HCL, Placebo
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
08/26
08/27
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting
2
120
RoW
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-alcoholic Steatohepatitis
12/26
12/27
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation
2
160
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
06/26
11/26
NCT06962865: A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Not yet recruiting
2
80
RoW
RC108, RC108 For Injection;, Furmonertinib Mesilate Tablets Monotherapy, Furmonertinib
RemeGen Co., Ltd.
Non-Small Cell Lung Cancer
05/26
12/27
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed
1/2
202
RoW
GR2001, Placebo, HTIG, Tetanus Toxoid
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Tetanus
11/23
02/24
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed
1/2
59
US, RoW
IMP4297(senaparib), temozolomide
Impact Therapeutics, Inc.
Advanced Solid Tumours, Small Cell Lung Cancer
04/24
04/24
NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting
1
60
RoW
HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Similarity of Pharmacokinetics and Safety
12/21
12/21
NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed
1
16
RoW
ABSK021 with fed state, ABSK021 with fasted state
Abbisko Therapeutics Co, Ltd
Neoplasms
08/22
05/23
NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting
1
102
RoW
SYHX 1901 tablets, Placebo
CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects
08/22
12/22
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed
1
20
RoW
IBI353 (Orismilast), placebo
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
11/22
12/22
NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed
1
32
RoW
TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg
Vigonvita Life Sciences
Healthy Subjects
12/22
12/22
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting
1
15
RoW
BAT4406F
Bio-Thera Solutions
Neuromyelitis Optica Spectrum Disorders
03/23
06/23
NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed
1
84
RoW
HS-10374 tablets, HS-10374-matched placebo tablets
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
03/23
03/23
NCT05511870: A Study of Etripamil in Healthy Subjects

Completed
1
12
RoW
Etripamil Nasal Spray 70mg, Placebo
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.
Healthy Chinese Subjects
03/23
03/23
NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed
1
252
RoW
HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®
Shanghai Henlius Biotech
Healthy Male Volunteers
09/23
09/23
NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed
1
32
RoW
Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin
Abbisko Therapeutics Co, Ltd
Healthy Subjects
08/23
09/23
NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed
1
38
RoW
Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg
Vigonvita Life Sciences
Healthy Subjects
09/23
09/23
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting
1
48
RoW
SG301 SC Injection, SG301 SC Placebo
Hangzhou Sumgen Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE)
05/25
10/25
NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting
1
80
RoW
JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts
Jemincare
Safety and Tolerability
12/23
03/24
SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting
1
37
NA
SGB-9768, Placebo
Suzhou Sanegene Bio Inc.
Healthy Volunteer
05/25
10/25
NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated
1
64
RoW
SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection
Suzhou Erye Pharmaceutical Co., Ltd.
Infections
05/24
05/24
NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting
1
70
RoW
JMKX003801, Placebo
Jemincare
Healthy
05/25
06/25
NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting
1
56
RoW
0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
10/24
10/24
NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed
1
24
RoW
TAK-279, Placebo
Takeda
Healthy Volunteers
07/24
08/24
NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting
1
56
RoW
GenSci120, Placebo
Changchun GeneScience Pharmaceutical Co., Ltd.
Autoimmune Disease
01/26
04/26
Zou, Hejian
NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed
3
313
RoW
genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan
Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Gout Arthritis
04/24
04/24
NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting
3
500
NA
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
12/24
11/25
NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting
3
200
RoW
SHR-1314 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriatic Arthritis
04/26
06/26
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
07/28
01/30
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
Gensci 048-202, NCT05936281: A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Completed
2
165
RoW
Genakumab for injection, Colchicine
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital
Gout, Gout Initiating Urate-loweringUrate-lowering Therapy
01/24
01/24
Gensci 048-203, NCT05936268: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Completed
2
106
RoW
Genakumab for injection, Colchicine
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital
Acute Gout, Gout Flare
02/24
02/24
NCT06176508: Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Recruiting
2
160
RoW
HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral
Hansoh BioMedical R&D Company
Psoriatic Arthritis
04/26
08/26
NCT06270225: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Active, not recruiting
2
157
RoW
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, SSGJ-613 100mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200mg, Colchicine 0.5 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout Arthritis
10/24
12/24
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed
2
84
RoW
Febuxostat, IBI128
Innovent Biologics (Suzhou) Co. Ltd.
Gout, Hyperuricemia
12/24
01/25
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT05588908: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Recruiting
1/2
120
RoW
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib), SSGJ-613 100 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib), SSGJ-613 200 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib), SSGJ-613 300 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II), SSGJ-613 200 mg (phase II), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II), SSGJ-613 300 mg (phase II), Compound Betamethasone Injection (phase II), Placebo (phase II), PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
09/23
11/23
Qin, Xiaoli
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
Wang, Le
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide(TMF), HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

Recruiting
4
100
RoW
Tenofovir Alafenamide 25 MG, Vemlidy
New Discovery LLC, Beijing Ditan Hospital
Hepatitis B, Chronic
09/23
09/23
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated
3
290
RoW
JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo
Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH
Moderate to Severe COVID-19
12/22
12/22
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19

Terminated
2/3
381
RoW
JT001, VV116, Placebo
Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH
Mild to Moderate COVID-19
03/23
03/23
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Recruiting
2/3
1188
RoW
FB2001, DC402234, FB2001 placebo
Frontier Biotechnologies Inc.
COVID-19
11/23
12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
07/27
07/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
Zhang, Jing
NCT05536726: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis

Completed
3
458
RoW
608 Q2W, 608 Q4W, Placebo, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
10/23
06/24
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Recruiting
3
360
Europe, US, RoW
Elamipretide, Elamipretide HCL, Placebo
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
08/26
08/27
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

Completed
3
361
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Respiratory Viral Infection
02/25
02/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

Recruiting
2
120
RoW
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-alcoholic Steatohepatitis
12/26
12/27
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Enrolling by invitation
2
160
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
06/26
11/26
NCT06962865: A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Not yet recruiting
2
80
RoW
RC108, RC108 For Injection;, Furmonertinib Mesilate Tablets Monotherapy, Furmonertinib
RemeGen Co., Ltd.
Non-Small Cell Lung Cancer
05/26
12/27
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT06302374: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Completed
1/2
202
RoW
GR2001, Placebo, HTIG, Tetanus Toxoid
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Tetanus
11/23
02/24
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Completed
1/2
59
US, RoW
IMP4297(senaparib), temozolomide
Impact Therapeutics, Inc.
Advanced Solid Tumours, Small Cell Lung Cancer
04/24
04/24
NCT04361812: Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

Not yet recruiting
1
60
RoW
HS632, Recombinant anti IgE humanized monoclonal antibody 150mg, Omalizumab (Xolair®), Omalizumab 150mg
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Similarity of Pharmacokinetics and Safety
12/21
12/21
NCT05280483: ABSK021 Food Effect Study in Healthy Subjects

Completed
1
16
RoW
ABSK021 with fed state, ABSK021 with fasted state
Abbisko Therapeutics Co, Ltd
Neoplasms
08/22
05/23
NCT04880512: The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

Recruiting
1
102
RoW
SYHX 1901 tablets, Placebo
CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Subjects
08/22
12/22
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
NCT05490316: A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Completed
1
20
RoW
IBI353 (Orismilast), placebo
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
11/22
12/22
NCT05750355: Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Completed
1
32
RoW
TPN171H 10 mg Group, TPN171H 10 mg, TPN171H 30 mg Group, TPN171H 30 mg, TPN171H 40 mg Group, TPN171H 40 mg, TPN171H 50 mg Group, TPN171H 50 mg
Vigonvita Life Sciences
Healthy Subjects
12/22
12/22
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Recruiting
1
15
RoW
BAT4406F
Bio-Thera Solutions
Neuromyelitis Optica Spectrum Disorders
03/23
06/23
NCT06033742: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Completed
1
84
RoW
HS-10374 tablets, HS-10374-matched placebo tablets
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
03/23
03/23
NCT05511870: A Study of Etripamil in Healthy Subjects

Completed
1
12
RoW
Etripamil Nasal Spray 70mg, Placebo
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Milestone Pharmaceuticals Inc.
Healthy Chinese Subjects
03/23
03/23
NCT04534582: Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

Completed
1
252
RoW
HLX14, EU-Prolia®, US-Prolia®, CN-Prolia®
Shanghai Henlius Biotech
Healthy Male Volunteers
09/23
09/23
NCT06089733: A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Completed
1
32
RoW
Part A ABSK201 and Itraconazole, Part A ABSK201 and Rifampicin
Abbisko Therapeutics Co, Ltd
Healthy Subjects
08/23
09/23
NCT05932459: A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

Completed
1
38
RoW
Deuremidevir Hydrobromide for Suspension 100mg, VV116, Deuremidevir Hydrobromide for Suspension 300mg, Deuremidevir Hydrobromide for Suspension 25mg, Deuremidevir Hydrobromide tablets 100mg
Vigonvita Life Sciences
Healthy Subjects
09/23
09/23
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Recruiting
1
48
RoW
SG301 SC Injection, SG301 SC Placebo
Hangzhou Sumgen Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE)
05/25
10/25
NCT05907382: Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Recruiting
1
80
RoW
JMKX003002 will be administered orally, JMKX003002, Placebo in Cohorts 1 to 5, Matching placebo will be administered orally, Placebo in 2 Cohorts
Jemincare
Safety and Tolerability
12/23
03/24
SGB-9768-002, NCT06501573: A Study of SGB-9768 in Adult Healthy Volunteers

Not yet recruiting
1
37
NA
SGB-9768, Placebo
Suzhou Sanegene Bio Inc.
Healthy Volunteer
05/25
10/25
NCT06055777: Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Terminated
1
64
RoW
SZEY-2108 for injetion, Novel monocyclic β-lactam antibiotics, Placebo, 0.9% Sodium Chloride Injection
Suzhou Erye Pharmaceutical Co., Ltd.
Infections
05/24
05/24
NCT06549309: Trial of JMKX003801 in Healthy Participants

Recruiting
1
70
RoW
JMKX003801, Placebo
Jemincare
Healthy
05/25
06/25
NCT05843422: A First-in-Human Study of QY211 Gel in Adult Subjects

Recruiting
1
56
RoW
0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo, 1.5% QY211 Gel or placebo
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
10/24
10/24
NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Completed
1
24
RoW
TAK-279, Placebo
Takeda
Healthy Volunteers
07/24
08/24
NCT06827457: A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

Recruiting
1
56
RoW
GenSci120, Placebo
Changchun GeneScience Pharmaceutical Co., Ltd.
Autoimmune Disease
01/26
04/26
Zou, Hejian
NCT05983445: Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Completed
3
313
RoW
genakumab, • Gensci048, placebo for Diprospan, placebo for genakumab, Diprospan
Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Gout Arthritis
04/24
04/24
NCT06169891: A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Not yet recruiting
3
500
NA
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200 mg, Placebo, 0.9% sodium chloride injection, Compound Betamethasone Injection, PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
12/24
11/25
NCT06640257: A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Recruiting
3
200
RoW
SHR-1314 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriatic Arthritis
04/26
06/26
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
3
225
RoW
Belimumab
GlaxoSmithKline, ICON plc
Bronchial Diseases
07/28
01/30
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
Gensci 048-202, NCT05936281: A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Completed
2
165
RoW
Genakumab for injection, Colchicine
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital
Gout, Gout Initiating Urate-loweringUrate-lowering Therapy
01/24
01/24
Gensci 048-203, NCT05936268: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Completed
2
106
RoW
Genakumab for injection, Colchicine
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital
Acute Gout, Gout Flare
02/24
02/24
NCT06176508: Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Recruiting
2
160
RoW
HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral
Hansoh BioMedical R&D Company
Psoriatic Arthritis
04/26
08/26
NCT06270225: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Active, not recruiting
2
157
RoW
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, SSGJ-613 100mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, SSGJ-613 200mg, Colchicine 0.5 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout Arthritis
10/24
12/24
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed
2
84
RoW
Febuxostat, IBI128
Innovent Biologics (Suzhou) Co. Ltd.
Gout, Hyperuricemia
12/24
01/25
NCT05328531: Clinical Study of Genakumab for Injection in Patients With Acute Gout

Completed
1/2
121
RoW
Genakumab for Injection, Placebo for Genakumab for Injection
Changchun GeneScience Pharmaceutical Co., Ltd., Huashan Hospital, Hainan General Hospital, Linyi People's Hospital, The Second Affiliated Hospital of Chongqing Medical University, Changhai Hospital, The First Affiliated Hospital with Nanjing Medical University, Shengjing Hospital, Affiliated Hospital of Nantong University
Acute Gout
06/22
06/22
NCT05588908: A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Recruiting
1/2
120
RoW
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib), SSGJ-613 100 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib), SSGJ-613 200 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib), SSGJ-613 300 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II), SSGJ-613 200 mg (phase II), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II), SSGJ-613 300 mg (phase II), Compound Betamethasone Injection (phase II), Placebo (phase II), PBO
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Gout
09/23
11/23
Qin, Xiaoli
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Completed
1
66
RoW
ZX-7101A, Placebo
Nanjing Zenshine Pharmaceuticals
Safety Issues, Tolerance, Pharmacokinetics, Food Effect
08/22
12/22
Wang, Le
No trials found

Download Options